June 23 (Reuters) - Passage Bio Inc PASG.O:
PASSAGE BIO REPORTS UPDATED INTERIM DATA FROM UPLIFT-D STUDY AND PROVIDES PROGRAM UPDATE
PASSAGE BIO INC - DOSE 1 PBFT02 SHOWS DURABLE INCREASE IN CSF PGRN LEVELS
PASSAGE BIO INC -REMAIN ON TRACK TO SEEK REGULATORY FEEDBACK ON FTD-GRN PIVOTAL TRIAL DESIGN IN 1H 2026
Source text: ID:nGNX98q5LK
Further company coverage: PASG.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.